Note 5 - Line of Credit
|3 Months Ended|
Mar. 31, 2021
|Line of Credit Facility [Abstract]|
|Line of Credit||
On November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company. The outstanding principal of all advances under the line of credit will bear interest at the rate of interest of prime plus 2% per annum.
As of March 31, 2021 and December 31, 2020, outstanding balance of this credit line amounted to $31,000, respectively.
Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef